Estrogen Receptor Negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Estrogen Receptor Negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-07-10Clinical Trial Update: Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer [Phase 2]
Phase II trial update of short-term adjuvant therapy and biomarker studies using targeted agents in women with estrogen receptor-negative br…
-
CLINICAL_TRIALS trial_result · 2023-11-09Clinical Trial Update: Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca [Phase 2]
Phase 2 trial evaluating neoadjuvant pembrolizumab plus decitabine followed by standard neoadjuvant chemotherapy for locally advanced HER2-n…
-
CLINICAL_TRIALS trial_result · 2022-04-25Clinical Trial Update: Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer [Phase 1]
Phase 1 trial investigating eribulin mesylate and everolimus in triple-negative metastatic breast cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-04-23Clinical Trial Update: MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer [Phase 2]
Phase 2 trial update evaluating MEDI4736 (durvalumab) and tremelimumab in metastatic HER2-negative breast cancer has completed with posted r…
-
CLINICAL_TRIALS trial_result · 2021-03-11Clinical Trial Update: Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer [Phase 2]
Phase II trial of the CDK inhibitor PD 0332991 (palbociclib) in various adult solid tumors including colon and breast cancers has completed …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-07-13Clinical Trial Update: Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery [Phase 2]
Phase 2 trial evaluating pembrolizumab with capecitabine for locally advanced or metastatic triple-negative breast cancer or hormone-refract…
-
CLINICAL_TRIALS trial_result · 2019-06-07Clinical Trial Update: Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients [Phase 2]
Phase 2 clinical trial update investigating carboplatin and eribulin mesylate in triple-negative breast cancer.
-
CLINICAL_TRIALS trial_result · 2018-12-04Clinical Trial Update: Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer [Phase 2]
Phase 2 trial evaluating nab-paclitaxel and bevacizumab followed by bevacizumab and erlotinib in metastatic breast cancer; completed with re…
-
CLINICAL_TRIALS trial_result · 2018-03-30Clinical Trial Update: Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer [Phase 1]
Phase 1 study evaluating the combination of dinaciclib and epirubicin hydrochloride in metastatic triple-negative breast cancer has complete…
-
CLINICAL_TRIALS trial_result · 2018-03-12Clinical Trial Update: Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery [Phase 2]
A Phase 2 trial evaluating pre-surgery chemotherapy with filgrastim in patients with HER2-positive breast cancer that could be surgically re…
-
CLINICAL_TRIALS trial_result · 2018-01-16Clinical Trial Update: Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer [Phase 2]
A phase 2 trial evaluating carboplatin with combination chemotherapy, with or without veliparib, in patients with stage IIB–IIIC breast canc…
-
CLINICAL_TRIALS trial_result · 2017-08-10Clinical Trial Update: Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer [Phase 1]
Phase 1 trial evaluating the combination of veliparib with cisplatin and vinorelbine ditartrate in patients with recurrent and/or metastatic…
-
CLINICAL_TRIALS trial_result · 2017-06-27Clinical Trial Update: GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer [Phase 1, Phase 2]
A phase 1/2 clinical trial of GDC-0941 (pictilisib) with cisplatin for androgen receptor-negative triple-negative metastatic breast cancer w…
-
CLINICAL_TRIALS trial_result · 2017-04-11Clinical Trial Update: Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer [Phase 2]
Phase 2 trial of RO4929097, a gamma-secretase/Notch pathway inhibitor, in advanced/metastatic/recurrent triple-negative breast cancer was te…
-
CLINICAL_TRIALS trial_result · 2016-09-29Clinical Trial Update: A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT) [Phase 2]
Phase II study evaluating androgen receptor–targeted therapy in pre-treated postmenopausal patients with ER/PR status and AR positivity in m…
-
CLINICAL_TRIALS trial_result · 2014-09-23Clinical Trial Update: Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating medroxyprogesterone with or without cyclophosphamide and methotrexate in estrogen receptor-negative and pr…
-
CLINICAL_TRIALS trial_result · 2014-01-20Clinical Trial Update: Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery [Phase 2]
This is a Phase 2 trial update of saracatinib for metastatic or unresectable locally advanced breast cancer. It includes estrogen receptor-n…